Clinical trial
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine…
NCT00353496 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00353496 |
|---|---|
| Title | Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours |
| Official title | Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning… |
| Acronym | CLARINET |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Endocrine Tumors |
| Intervention type | Drug |
| Interventions | lanreotide (Autogel formulation), Placebo |
| Enrollment | 264 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2013 |
| Completion | Apr 1, 2013 |
| First posted | Jul 18, 2006 |
| Last update posted | Mar 5, 2025 |
| Countries | Austria, Belgium, Czechia, Denmark, France, Germany, India, Italy, Netherlands, Poland, Slovakia, Spain and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: